Seaport Therapeutics’ Post

We are pleased to welcome Antony Loebel, M.D., as Chief Medical Officer and President of Clinical Development, and Lana Gladstein, J.D. as General Counsel at Seaport. A CNS drug development expert, Dr. Loebel was the former Chief Executive Officer and Chief Medical Officer at Sunovion Pharmaceuticals. An experienced attorney, Lana brings over two decades of legal expertise, including corporate governance, navigating M&A transactions, licensing and partnerships, and intellectual property matters. Commenting on the appointments, Daphne Zohar, Founder and CEO of Seaport said: “I’m delighted to welcome two more outstanding members to our senior executive team. As we design and run studies to advance our clinical-stage pipeline of novel therapeutics focused on important mental health conditions, Tony’s deep understanding of neuropsychiatric drug development builds on our team’s distinct advantages. We are rapidly growing our company and Lana’s experience across all facets of legal, including corporate governance, transactions, and IP, will be an important resource to Seaport. I’m thrilled to have both Tony and Lana onboard.” https://lnkd.in/exdWvKai

Nice overview by Nature Biotech of next-generation psychedelic drugs including SPT-348, a prodrug of a non-hallucinogenic neuroplastogen. Across our clinical-stage pipeline, we're advancing candidates to treat #depression, #anxiety & other #neuropsychiatric disorders. https://lnkd.in/e26KpcTb

Our Co-founder and Chief Scientific Officer Michael C. Chen will present data from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting (#SOBP2024). The data summarizes some of the evidence supporting the core mechanisms of SPT-300 and support our planned studies in mood and #anxiety disorders, including anxious #depression https://bit.ly/3JReH4Q

Join us in recognizing #MentalHealthAwarenessMonth, an initiative to bring attention to the importance of #mentalhealth. Major #depression and #anxiety disorders are among the most common, disabling and potentially fatal of all medical conditions. At Seaport, we are dedicated to solving the challenges of treating serious mental health conditions and bringing new medicines to those that are suffering from depression, anxiety and other #neuropsychiatric disorders.

Earlier this week, our CEO Daphne Zohar joined Douglas Banks, Barry Greene, Sharon Cunningham and Michael Nally on the main stage at MassBio’s State of Possible Conference for the Success in Choppy Waters panel discussion. It was an inspiring day that brought together the local biopharma community to discuss the important issues facing our industry and how we can work collectively to deliver important new medicines to patients. #StateOfPossible2024

We’re pleased to launch Seaport Therapeutics today with the closing of a $100 million oversubscribed Series A financing round, co-led by ARCH Venture Partners, Sofinnova Investments Investments, along with Third Rock Ventures and Seaport founder PureTech Health.   Seaport is founded and led by a team of industry veterans that were involved in inventing and advancing KarXT and other neuropsychiatric medicines, including Daphne Zohar, Founder, CEO and Board Member, and Steven Paul, Founder and Chair of the Board of Directors. The financing will support the rapid advancement of Seaport’s clinical-stage pipeline of novel neuropsychiatry medicines in areas of high unmet patient needs. https://bit.ly/3TPnU2b